Name (Synonyms) | Correlation | |
---|---|---|
drug2843 | hydroxychloroquine placebo Wiki | 1.00 |
drug2840 | hydroxychloroquine Wiki | 0.50 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The Investigators propose to set up a preventive trial of infection in hospital workers at risk of coronavirus infection by comparing the rate of SARS-Cov-2 infection in a population of negative SARS-Cov-2 hospital workers receiving preventively azithromycin, hydroxychloroquine or a Placebo
Description: The number of hospital workers with a positive serology or a positive PCR within 40 days of follow-up.
Measure: To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment. Time: 3 monthsDescription: Clinical signs suggesting SARS-2 CoV infection confirmed by positive endonasal PCR
Measure: Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR Time: 40 daysDescription: number of seroconversion by serology between Day 0 and Day 40.
Measure: Reducing seroconversion for SARS-CoV-2 without any clinical sign Time: 3 monthsDescription: number of cardiological severe adverse events assessed (ECG abnormalities : widening QT, ventricular arythmia, and cardiac arrests), other serious adverse events including hospitalizations, and deaths
Measure: Evaluation of drug tolerance in the study Time: 40 daysDescription: Number of work stoppages over the period
Measure: Evaluation on work stopping of hospital workers Time: 40 daysDescription: Plasmatic concentrations of treatments
Measure: Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine Time: 40 daysDescription: number of cardiac events, especialy ECG abnormalities (widening QT) due to treatments
Measure: Incidence of cardiologic events Time: 40 days